晨暉生技 1271.TW Overview

1271 Key Information

1271 Revenue by Segments

Browsing restrictions can be lifted for a fee.

1271 Net Income

Browsing restrictions can be lifted for a fee.

1271 Cash Flow

Browsing restrictions can be lifted for a fee.

1271 Profit Margin

Browsing restrictions can be lifted for a fee.

1271 PE Ratio River

Browsing restrictions can be lifted for a fee.

1271 FAQ

• When is 1271's latest earnings report released?

  The most recent financial report for 晨暉生技 (1271) covers the period of 2024Q4 and was published on 2024/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1271's short-term business performance and financial health. For the latest updates on 1271's earnings releases, visit this page regularly.

• Where does 1271 fall in the P/E River chart?

  According to historical valuation range analysis, 晨暉生技 (1271)'s current price-to-earnings (P/E) ratio is 33.28, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

• What is the operating profit of 1271?

  According to the latest financial report, 晨暉生技 (1271) reported an Operating Profit of 56.75M with an Operating Margin of 11.65% this period, representing a growth of 3,121.94% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

• How is 1271's revenue growth?

  In the latest financial report, 晨暉生技 (1271) announced revenue of 487.12M, with a Year-Over-Year growth rate of 15.08%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

• How much cash does 1271 have?

  At the end of the period, 晨暉生技 (1271) held Total Cash and Cash Equivalents of 293.71M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

• Does 1271 go with three margins increasing?

  In the latest report, 晨暉生技 (1271) achieved the “three margins increasing” benchmark, with a gross margin of 54.36%%, operating margin of 11.65%%, and net margin of 9.67%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1271's profit trajectory and future growth potential.

• Is 1271's EPS continuing to grow?

  According to the past four quarterly reports, 晨暉生技 (1271)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.78. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

• What is the FCF of 1271?

  晨暉生技 (1271)'s Free Cash Flow (FCF) for the period is 10.44M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 102.99% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.